Resumen de acción MNOV MediciNova, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias novedosas y de moléculas pequeñas para el tratamiento de enfermedades graves con necesidades médicas no cubiertas en Estados Unidos. Saber más
Análisis de riesgos Ver todos los controles de riesgos Captura tus ideas, enlaces y narrativas de la empresa
Competidores de MediciNova, Inc. Historial de precios y rendimiento
Resumen de las cotizaciones máximas, mínimas y variaciones del MediciNova Precios históricos de las acciones Precio actual de la acción US$2.07 Máximo en las últimas 52 semanas US$2.55 Mínimo de 52 semanas US$1.12 Beta 0.85 Cambio en 1 mes -0.48% Variación en 3 meses 8.38% Cambio de 1 año 46.81% Variación en 3 años -23.05% Variación en 5 años -69.01% Variación desde la OPV -81.10%
Noticias y actualizaciones recientes
Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver Nov 15
MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 30
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) Oct 01
MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition Aug 30
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth Aug 28
MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 10 Ver más actualizaciones
Medicinova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver Nov 15
MediciNova, Inc. to Report Q3, 2024 Results on Nov 14, 2024 Oct 30
MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS) Oct 01
MediciNova, Inc. Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition Aug 30
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth Aug 28
MediciNova, Inc. to Report Q2, 2024 Results on Aug 09, 2024 Jul 10
MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer Jun 06
MediciNova, Inc. Announces Data from Phase 1B/2A Clinical Trial of Mn-166 (Ibudilast) in Glioblastoma Patients At the American Society of Clinical Oncology (Asco) Annual Meeting 2024 Jun 05
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome May 15
MediciNova, Inc. Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) May 08
MediciNova, Inc., Annual General Meeting, Jun 11, 2024 Apr 28
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely Apr 19
MediciNova, Inc. to Report Q1, 2024 Results on May 10, 2024 Apr 12
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan Mar 27
Medicinova Announces New Data and Results of Mn-166 (Ibudilast) in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology Mar 12
Price target increased by 69% to US$27.00 Feb 22
MediciNova, Inc. to Report Fiscal Year 2023 Results on Feb 14, 2024 Jan 22
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China Jan 17
MediciNova, Inc. Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology Dec 22
MediciNova, Inc. Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe Dec 07
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans Nov 27
MediciNova, Inc. to Report Q3, 2023 Results on Nov 10, 2023 Oct 08
Price target decreased by 41% to US$16.00 Aug 24
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology Aug 19 MediciNova, Inc. Receives A Notice of Intention to Grant for A New Patent Covering MN-166 (Ibudilast) for the Treatment of Macular Injury in Europe
Less than half of directors are independent Aug 13
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely Jul 11
MediciNova, Inc. Announces Presentation of Results from the Phase 2B Trial of Mn-166 (Ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting Jun 30
Here's Why We're Not Too Worried About MediciNova's (NASDAQ:MNOV) Cash Burn Situation Mar 18
MediciNova Announces Health Canada Grants Authorization to Commence Multi-Arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID Feb 09
MediciNova, Inc. Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder Jan 31
MediciNova, Inc. Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma Jan 13
MediciNova Receives Notice of Allowance for A New Patent Covering Mn-001 and Mn-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada Jan 12
MediciNova, Inc. Receives Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil Jan 10
MediciNova, Inc. Completes Phase I Clinical Trial to Evaluate MN-166 10 MG Intravenous Infusion in Healthy Volunteers Jan 06
MediciNova, Inc. Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presents at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation Dec 08
Price target decreased to US$13.00 Nov 16
We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth Oct 12
MediciNova, Inc. to Report Q3, 2022 Results on Nov 11, 2022 Oct 06
MediciNova to get US patent for MN-166 to treat brain cancer Sep 15
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Canada Sep 14
MediciNova's MN-166 to be part of study to treat Long COVID Aug 16
First half 2022 earnings released Aug 12
MediciNova Receives Notice of Allowance for New Patent Covering MN-001 and MN-002 for the Treatment of Fibrosis in Korea Jul 28
MediciNova, Inc Announces Initiation of a Phase 2 Trial of MN-001 (tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia Jul 27
MediciNova, Inc. to Report Q2, 2022 Results on Aug 12, 2022 Jul 24
MediciNova, Inc. Initiates Clinical Evaluation of a New Parenteral Formulation of MN-166 (ibudilast) Jul 22
MediciNova begins study of parenteral formulation of MN-166 Jul 22
MediciNova announces extension of BARDA contract for Ibudilast development Jun 30
MediciNova, Inc. Announces Executive Changes Jun 22 MediciNova, Inc. Announces Positive Top-Line Results from Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome Jun 09
Price target decreased to US$13.00 Apr 27
MediciNova, Inc. to Report Q1, 2022 Results on May 13, 2022 Apr 24
MediciNova, Inc. Announces Publication of MN-166 (ibudilast) Data regarding Prevention of Metastasis in Uveal Melanoma in Molecular Cancer Research Apr 21
MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome Apr 13
MediciNova, Inc. Announces Plans for A Phase 2 Trial of Mn-001 (Tipelukast) in Nafld with Type 2 Diabetes Mellitus and Hypertriglyceridemia Apr 12
MediciNova, Inc. Announces Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Alcoholism: Clinical and Experimental Research Apr 08
We're Hopeful That MediciNova (NASDAQ:MNOV) Will Use Its Cash Wisely Mar 19
MediciNova, Inc. announces MN-166 (ibudilast) Identified as Promising Pharmacotherapy for Alcohol Use Disorder in Drugs Feb 24
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for Hepatic Ballooning in Canada Feb 01
MediciNova Receives Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Alcohol Use Disorder in Europe Jan 28
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of ALS Dec 15
MediciNova, Inc. Announces MN-166 (ibudilast) Poster Presentation at the 32nd International Symposium on ALS/MND Dec 11
Medicinova, Inc. Announces New Data Regarding Mn-166 (ibudilast) in Glioblastoma Presented At the 26Th Annual Meeting of the Society for Neuro-Oncology Nov 24
MediciNova (NASDAQ:MNOV) Is In A Strong Position To Grow Its Business Nov 23
MediciNova, Inc. Announces MN-166 (ibudilast) ALS Abstract Accepted for Presentation at the 32nd International Symposium on ALS/MND Aug 31
MediciNova: The Pain Of A Positive Outlook Aug 31
Price target decreased to US$16.00 Aug 27
Chief Medical Officer & Director exercised options to buy US$229k worth of stock. Aug 26
Consensus revenue estimates increase to US$15.5m Aug 19
Chief Financial Officer Edward Stepanow has left the company Aug 04 MediciNova, Inc.(NasdaqGM:MNOV) dropped from Russell 3000 Growth Index
MediciNova, Inc. Announces Positive Results from Phase 2 Trial of MN-166 (ibudilast) in Alcohol Use Disorder Published in Nature’s Translational Psychiatry Journal Jun 22
MediciNova stock climbs 31% on positive MN-166 data in mid-stage alcohol use disorder study Jun 21
MediciNova Initiates Sheep Study under Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury Jun 08
Companies Like MediciNova (NASDAQ:MNOV) Are In A Position To Invest In Growth May 15
MediciNova, Inc. a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe May 06
The MediciNova Riddle: Worth Unravelling Apr 26
New 90-day high: US$8.74 Mar 11
MediciNova, Inc. Announces Partnership with BARDA to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-Induced Lung Injury Mar 10
MediciNova, Inc. Announces Update on SARS-CoV-2 Vaccine for Covid-19 Mar 05
Co-Founder exercised options to buy US$492k worth of stock. Mar 03
Analysts increase revenue estimates to US$39.5m Feb 27
New 90-day high: US$6.36 Feb 05
MediciNova, Inc. announced that it has received $19.999999 million in funding from 3D Investment Partners Pte. Ltd Feb 02
MediciNova, Inc. Receives Notice of Allowance for New Patent Covering the Combination of MN-166 (Ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis in Japan Jan 20
MediciNova, Inc. announced that it expects to receive $19.999999 million in funding from 3D Investment Partners Pte. Ltd Jan 13
MediciNova inks $20M securities purchase agreement with 3D Investment Partners Jan 12
Medicinova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS Dec 30
MediciNova nabs new U.S. patent for ibudilast in multiple sclerosis Dec 29
MediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth Plans Dec 29 Rentabilidad de los accionistas MNOV US Biotechs Mercado US 7D -4.2% 2.1% 2.8% 1Y 46.8% -3.8% 24.5%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: MNOV superó a la industria US Biotechs, que obtuvo un rendimiento del -3.8% el año pasado.
Rentabilidad vs. Mercado: MNOV superó al mercado US, que obtuvo un rendimiento del 24.5% el año pasado.
Volatilidad de los precios Is MNOV's price volatile compared to industry and market? MNOV volatility MNOV Average Weekly Movement 16.8% Biotechs Industry Average Movement 10.7% Market Average Movement 6.3% 10% most volatile stocks in US Market 17.1% 10% least volatile stocks in US Market 3.1%
Precio estable de las acciones: El precio de las acciones de MNOV ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de MNOV ha aumentado de 11% a 17% en el último año.
Acerca de la empresa MediciNova, Inc. es una empresa biofarmacéutica centrada en el desarrollo de terapias novedosas y de moléculas pequeñas para el tratamiento de enfermedades graves con necesidades médicas no cubiertas en Estados Unidos. Está desarrollando MN-166 (ibudilast), un agente antiinflamatorio y neuroprotector oral para el tratamiento de trastornos neurológicos y de otro tipo, como la esclerosis múltiple primaria y secundaria progresiva, la esclerosis lateral amiotrófica, la neuropatía periférica inducida por la quimioterapia, la mielopatía cervical degenerativa, el glioblastoma y la dependencia y adicción a sustancias, así como la prevención del síndrome de dificultad respiratoria aguda, y el COVID largo. La cartera de productos de la empresa también incluye MN-221 (bedoradrina), un agonista selectivo de los receptores beta-2 adrenérgicos para el tratamiento de las exacerbaciones agudas del asma; MN-001 (tipelukast), un compuesto de molécula pequeña biodisponible por vía oral para tratar enfermedades fibróticas y de otro tipo, como la enfermedad del hígado graso no alcohólico y la fibrosis pulmonar idiopática; y MN-029 (denibulina), un agente de unión a la tubulina para tratar cánceres de tumores sólidos.
Mostrar más Resumen de fundamentos de MediciNova, Inc. ¿Cómo se comparan los beneficios e ingresos de MediciNova con su capitalización de mercado? Estadísticas fundamentales de MNOV Capitalización bursátil US$101.53m Beneficios(TTM ) -US$10.29m Ingresos (TTM ) n/a
0.0x Ratio precio-ventas (PS)
-9.9x Ratio precio-beneficio (PE) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de MNOV Ingresos US$0 Coste de los ingresos US$0 Beneficio bruto US$0 Otros gastos US$10.29m Beneficios -US$10.29m
Últimos beneficios comunicados
Sep 30, 2024
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) -0.21 Margen bruto 0.00% Margen de beneficio neto 0.00% Ratio deuda/patrimonio 0%
¿Cómo se ha desempeñado MNOV a largo plazo?
Ver rendimiento histórico y comparativa
Análisis de la empresa y estado de los datos financieros Datos Última actualización (huso horario UTC) Análisis de la empresa 2024/12/26 09:00 Precio de las acciones al final del día 2024/12/24 00:00 Beneficios 2024/09/30 Ingresos anuales 2023/12/31
Fuentes de datos Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC . Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
Paquete Datos Marco temporal Ejemplo Fuente EE.UU. * Finanzas de la empresa 10 años Cuenta de resultados Estado de tesorería Balance Estimaciones del consenso de analistas +3 años Previsiones financieras Objetivos de precios de los analistas Precios de mercado 30 años Precios de las acciones Dividendos, escisiones y acciones Propiedad 10 años Accionistas principales Información privilegiada Gestión 10 años Equipo directivo Consejo de Administración Principales avances 10 años
* ejemplo para los valores estadounidenses, para los no estadounidenses se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Obtenga más información aquí .
Modelo de análisis y copo de nieve Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github , también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube .
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en .
Fuentes analistas MediciNova, Inc. está cubierta por 10 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
Analista Institución David Buck B. Riley Securities, Inc. Yen Ting Chen Credit Suisse Jason Kolbert D. Boral Capital LLC.
Mostrar 7 más analistas 
